Delta-Fly Pharma, Inc. (TYO:4598)

Delta-Fly Pharma Income Statement

Financials in millions JPY. Fiscal year is April - March.

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Revenue	-	-	-	-	300
Gross Profit	-	-	-	-	300
Selling, General & Admin	276	212	229	261	287
Research & Development	1,329	1,437	1,118	1,011	940
Other Operating Expenses	-	59	56	43	34
Operating Expenses	1,605	1,708	1,403	1,315	1,261
Operating Income	-1,605	-1,708	-1,403	-1,315	-961
Currency Exchange Gain (Loss)	-	-1	-5	-5	-
Other Non Operating Income (Expenses)	-18	-10	-19	-5	-3
Pretax Income	-1,623	-1,719	-1,427	-1,325	-964
Income Tax Expense	2	2	2	3	3
Net Income	-1,625	-1,721	-1,429	-1,328	-967
Net Income to Common	-1,625	-1,721	-1,429	-1,328	-967
Shares Outstanding (Basic)	12	9	7	6	5
Shares Outstanding (Diluted)	12	9	7	6	5
Shares Change (YoY)	31.55%	22.38%	26.91%	4.61%	17.64%
EPS (Basic)	-140.37	-195.56	-198.72	-234.37	-178.52
EPS (Diluted)	-140.37	-195.56	-198.72	-234.37	-178.52
Free Cash Flow	-1,557	-1,834	-1,280	-1,303	-940
Free Cash Flow Per Share	-134.50	-208.41	-178.00	-229.96	-173.54
Gross Margin	-	-	-	-	100.00%
Operating Margin	-	-	-	-	-320.33%
Profit Margin	-	-	-	-	-322.33%
Free Cash Flow Margin	-	-	-	-	-313.33%
EBITDA	-1,604	-1,707	-1,402	-1,314	-960
D&A For EBITDA	1	1	1	1	1
EBIT	-1,605	-1,708	-1,403	-1,315	-961

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jun 1, 2026

Data Sources Report a data error